12 research outputs found
Deep neural networks for unsupervised damage detection on the Z24 bridge
During their life-cycle, civil infrastructures are continuously prone to significant functionality losses, primarily due to material's degradation and exposure to several natural hazards. Following these concerns, many researchers have attempted to develop reliable monitoring strategies, as integration to visual inspections, to efficiently ensure bridge maintenance and early-stage damage detection. In this framework, recent improvements in sensor technologies and data science have stimulated the use of Machine Learning (ML) algorithms for Structural Health Monitoring (SHM). Among unsupervised learning techniques, the potential of autoencoder networks has been attracting notable interest in the context of anomaly detection. In this light, the present paper proposes two different autoencoder-based damage detection techniques, focused on the Multi-Layer Perceptron (MLP) and the Convolutional Autoencoder (CAE) networks, respectively. During the training, the selected ML models learn how reconstructing raw acceleration sequences acquired from sound conditions. Unknown data, including both healthy and damaged bridge responses, are afterwards used to test the implemented networks and to detect damage occurrence. To this aim, a specific index of reconstruction loss is selected as a damage sensitive feature with the aim to quantify the errors between the original and reconstructed sequences. The performance exhibited by the two approaches is compared and evaluated by application to the Z24 benchmark bridge. Results demonstrate the effectiveness of the proposed methodology to perform feature classification and real time damage detection at the level of macro-sequences as new sensor data is collected, resulting suitable for continuous assessment of full-scale monitored bridges
The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells
BACKGROUND:
Activation of wild-type p53 in response to genotoxic stress occurs through different mechanisms including protein conformation, posttranslational modifications, and nuclear localization, leading to DNA binding to sequence-specific promoters. Zinc ion plays a crucial role in stabilizing p53/DNA binding to induce canonical target genes. Mutant p53 proteins undergo protein misfolding that can be counteracted by zinc. However, whether zinc supplementation might have a beneficial antitumor effect in wild-type p53-carrying cells in combination with drugs, has not been addressed so far.
METHODS:
In this study we compared the effect of two antitumor treatments: on the one hand wild-type p53-carrying colon cancer cells were treated with low and high doses of chemotherapeutic agent Adriamycin and, on the other hand, Adriamycin was used in combination with ZnCl2. Biochemical and molecular analyses were applied to evaluate p53 activity and biological outcomes in this setting. Finally, the effect of the different combination treatments were applied to assess tumor growth in vivo in tumor xenografts.
RESULTS:
We found that low-dose Adriamycin did not induce p53 activation in wtp53-carrying colon cancer cells, unless in combination with ZnCl2. Mechanistically, ZnCl2 was a key determinant in inducing wtp53/DNA binding and transactivation of target genes in response to low-dose Adriamycin that used alone did not achieve such effects. Finally, in vivo studies, in a model of wtp53 colon cancer xenograft, show that low-dose Adriamycin did not induce tumor regression unless in combination with ZnCl2 that activated endogenous wtp53.
CONCLUSIONS:
These results provide evidence that ZnCl2 might be a valuable adjuvant in chemotherapeutic regimens of colorectal cancer harboring wild-type p53, able to both activate p53 and reduce the amount of drugs for antitumor purposes
Genomic evaluation of multiparametric magnetic resonance imaging-visible and -nonvisible lesions in clinically localised prostate cancer
Background:
The prostate cancer (PCa) diagnostic pathway is undergoing a radical change with the introduction of multiparametric magnetic resonance imaging (mpMRI), genomic testing, and different prostate biopsy techniques. It has been proposed that these tests should be used in a sequential manner to optimise risk stratification.
Objective:
To characterise the genomic, epigenomic, and transcriptomic features of mpMRI-visible and -nonvisible PCa in clinically localised disease.
Design, setting, and participants:
Multicore analysis of fresh prostate tissue sampled immediately after radical prostatectomy was performed for intermediate- to high-risk PCa.
Intervention:
Low-pass whole-genome, exome, methylation, and transcriptome profiling of patient tissue cores taken from microscopically benign and cancerous areas in the same prostate. Circulating free and germline DNA was assessed from the blood of five patients.
Outcome measurement and statistical analysis:
Correlations between preoperative mpMRI and genomic characteristics of tumour and benign prostate samples were assessed. Gene profiles for individual tumour cores were correlated with existing genomic classifiers currently used for prognostication.
Results and limitations:
A total of 43 prostate cores (22 tumour and 21 benign) were profiled from six whole prostate glands. Of the 22 tumour cores, 16 were tumours visible and six were tumours nonvisible on mpMRI. Intratumour genomic, epigenomic, and transcriptomic heterogeneity was found within mpMRI-visible lesions. This could potentially lead to misclassification of patients using signatures based on copy number or RNA expression. Moreover, three of the six cores obtained from mpMRI-nonvisible tumours harboured one or more genetic alterations commonly observed in metastatic castration-resistant PCa. No circulating free DNA alterations were found. Limitations include the small cohort size and lack of follow-up.
Conclusions:
Our study supports the continued use of systematic prostate sampling in addition to mpMRI, as avoidance of systematic biopsies in patients with negative mpMRI may mean that clinically significant tumours harbouring genetic alterations commonly seen in metastatic PCa are missed. Furthermore, there is inconsistency in individual genomics when genomic classifiers are applied.
Patient summary:
Our study shows that tumour heterogeneity within prostate tumours visible on multiparametric magnetic resonance imaging (mpMRI) can lead to misclassification of patients if only one core is used for genomic analysis. In addition, some cancers that were missed by mpMRI had genomic aberrations that are commonly seen in advanced metastatic prostate cancer. Avoiding biopsies in mpMRI-negative cases may mean that such potentially lethal cancers are missed
Gamma-Ray Burst observations by the high-energy charged particle detector on board the CSES-01 satellite between 2019 and 2021
In this paper we report the detection of five strong Gamma-Ray Bursts (GRBs)
by the High-Energy Particle Detector (HEPD-01) mounted on board the China
Seismo-Electromagnetic Satellite (CSES-01), operational since 2018 on a
Sun-synchronous polar orbit at a 507 km altitude and 97
inclination. HEPD-01 was designed to detect high-energy electrons in the energy
range 3 - 100 MeV, protons in the range 30 - 300 MeV, and light nuclei in the
range 30 - 300 MeV/n. Nonetheless, Monte Carlo simulations have shown HEPD-01
is sensitive to gamma-ray photons in the energy range 300 keV - 50 MeV, even if
with a moderate effective area above 5 MeV. A dedicated time correlation
analysis between GRBs reported in literature and signals from a set of HEPD-01
trigger configuration masks has confirmed the anticipated detector sensitivity
to high-energy photons. A comparison between the simultaneous time profiles of
HEPD-01 electron fluxes and photons from GRB190114C, GRB190305A, GRB190928A,
GRB200826B and GRB211211A has shown a remarkable similarity, in spite of the
different energy ranges. The high-energy response, with peak sensitivity at
about 2 MeV, and moderate effective area of the detector in the actual flight
configuration explain why these five GRBs, characterised by a fluence above
3 10 erg cm in the energy interval 300 keV - 50
MeV, have been detected.Comment: Accepted for publication in The Astrophysical Journal (ApJ
The Athena X-ray Integral Field Unit: a consolidated design for the system requirement review of the preliminary definition phase
The Athena X-ray Integral Unit (X-IFU) is the high resolution X-ray
spectrometer, studied since 2015 for flying in the mid-30s on the Athena space
X-ray Observatory, a versatile observatory designed to address the Hot and
Energetic Universe science theme, selected in November 2013 by the Survey
Science Committee. Based on a large format array of Transition Edge Sensors
(TES), it aims to provide spatially resolved X-ray spectroscopy, with a
spectral resolution of 2.5 eV (up to 7 keV) over an hexagonal field of view of
5 arc minutes (equivalent diameter). The X-IFU entered its System Requirement
Review (SRR) in June 2022, at about the same time when ESA called for an
overall X-IFU redesign (including the X-IFU cryostat and the cooling chain),
due to an unanticipated cost overrun of Athena. In this paper, after
illustrating the breakthrough capabilities of the X-IFU, we describe the
instrument as presented at its SRR, browsing through all the subsystems and
associated requirements. We then show the instrument budgets, with a particular
emphasis on the anticipated budgets of some of its key performance parameters.
Finally we briefly discuss on the ongoing key technology demonstration
activities, the calibration and the activities foreseen in the X-IFU Instrument
Science Center, and touch on communication and outreach activities, the
consortium organisation, and finally on the life cycle assessment of X-IFU
aiming at minimising the environmental footprint, associated with the
development of the instrument. Thanks to the studies conducted so far on X-IFU,
it is expected that along the design-to-cost exercise requested by ESA, the
X-IFU will maintain flagship capabilities in spatially resolved high resolution
X-ray spectroscopy, enabling most of the original X-IFU related scientific
objectives of the Athena mission to be retained. (abridged).Comment: 48 pages, 29 figures, Accepted for publication in Experimental
Astronomy with minor editin
The Athena X-ray Integral Field Unit: a consolidated design for the system requirement review of the preliminary definition phase
The Athena X-ray Integral Unit (X-IFU) is the high resolution X-ray spectrometer studied since 2015 for flying in the mid-30s on the Athena space X-ray Observatory. Athena is a versatile observatory designed to address the Hot and Energetic Universe science theme, as selected in November 2013 by the Survey Science Committee. Based on a large format array of Transition Edge Sensors (TES), X-IFU aims to provide spatially resolved X-ray spectroscopy, with a spectral resolution of 2.5 eV (up to 7 keV) over a hexagonal field of view of 5 arc minutes (equivalent diameter). The X-IFU entered its System Requirement Review (SRR) in June 2022, at about the same time when ESA called for an overall X-IFU redesign (including the X-IFU cryostat and the cooling chain), due to an unanticipated cost overrun of Athena. In this paper, after illustrating the breakthrough capabilities of the X-IFU, we describe the instrument as presented at its SRR (i.e. in the course of its preliminary definition phase, so-called B1), browsing through all the subsystems and associated requirements. We then show the instrument budgets, with a particular emphasis on the anticipated budgets of some of its key performance parameters, such as the instrument efficiency, spectral resolution, energy scale knowledge, count rate capability, non X-ray background and target of opportunity efficiency. Finally, we briefly discuss the ongoing key technology demonstration activities, the calibration and the activities foreseen in the X-IFU Instrument Science Center, touch on communication and outreach activities, the consortium organisation and the life cycle assessment of X-IFU aiming at minimising the environmental footprint, associated with the development of the instrument. Thanks to the studies conducted so far on X-IFU, it is expected that along the design-to-cost exercise requested by ESA, the X-IFU will maintain flagship capabilities in spatially resolved high resolution X-ray spectroscopy, enabling most of the original X-IFU related scientific objectives of the Athena mission to be retained. The X-IFU will be provided by an international consortium led by France, The Netherlands and Italy, with ESA member state contributions from Belgium, Czech Republic, Finland, Germany, Poland, Spain, Switzerland, with additional contributions from the United States and Japan.The French contribution to X-IFU is funded by CNES, CNRS and CEA. This work has been also supported by ASI (Italian Space Agency) through the Contract 2019-27-HH.0, and by the ESA (European Space Agency) Core Technology Program (CTP) Contract No. 4000114932/15/NL/BW and the AREMBES - ESA CTP No.4000116655/16/NL/BW. This publication is part of grant RTI2018-096686-B-C21 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. This publication is part of grant RTI2018-096686-B-C21 and PID2020-115325GB-C31 funded by MCIN/AEI/10.13039/501100011033
The importance of a molecular cytogenetic analysis before using cell lines in research : the case of the KG-1a leukemia cell line
The KG-1 and its less differentiated subline KG-1a are leukemia cell lines used in research in many laboratories. The karyotypes of the two lines were initially identical. Over the years, further analysis revealed that they had acquired additional karyotypical abnormalities and that differed for the presence of some typical chromosomal rearrangements. To obtain a cytogenetic authentication before the use these two cell lines, we analysed their karyotype combining DAPI- and CMA-chromosome bandings, and a FISH-based approach by using BAC clones useful for the identification of chromosome regions of interest. Particularly, sequences of the genes MYC, PLZF, RARA and BCR that are known to play a critical role in leukemogenesis, and some BAC clones mapped to five known common fragile sites were used for the FISH analysis. Moreover, we used a telomeric probe (TTAGGG)n, and a set of BAC clones to characterize the marker chromosome der(1) that we observed in the cell line KG-1a. The existence of notably differences between the karyotype of the KG-1a cell line previously described and that described by us demonstrate as it would be advisable that the utilization of established cancer cell lines is preceded by a cytogenetic and/or molecular characterization
Evidence of an upper ionospheric electric field perturbation correlated with a gamma ray burst
Abstract Earth’s atmosphere, whose ionization stability plays a fundamental role for the evolution and endurance of life, is exposed to the effect of cosmic explosions producing high energy Gamma-ray-bursts. Being able to abruptly increase the atmospheric ionization, they might deplete stratospheric ozone on a global scale. During the last decades, an average of more than one Gamma-ray-burst per day were recorded. Nevertheless, measurable effects on the ionosphere were rarely observed, in any case on its bottom-side (from about 60 km up to about 350 km of altitude). Here, we report evidence of an intense top-side (about 500 km) ionospheric perturbation induced by significant sudden ionospheric disturbance, and a large variation of the ionospheric electric field at 500 km, which are both correlated with the October 9, 2022 Gamma-ray-burst (GRB221009A)